When did Desoxyn receive FDA approval?
Desoxyn, the brand name for methamphetamine hydrochloride, was first approved by the U.S. Food and Drug Administration in 1937. The approval granted the drug the right to be prescribed for conditions such as attention‑deficit/hyperactivity disorder (ADHD), obesity, and narcolepsy. [1]
How long has Desoxyn been on the market?
Since its 1937 approval, Desoxyn has been available for more than eight decades. The drug’s long history reflects its continued, though limited, use in treating stimulant‑responsive disorders.
Who owns Desoxyn now and what’s its patent status?
Desoxyn is currently manufactured by Pfizer, Inc. The original patents protecting the drug have long expired, and the formulation is now in the public domain, allowing generic versions to be produced. [1]
What makes Desoxyn different from other stimulants like Adderall or Ritalin?
Desoxyn delivers a pure, potent form of methamphetamine, which produces a stronger central nervous system stimulation. Because of its high abuse potential, prescribing guidelines are stricter, and it is typically reserved for patients who do not respond to other stimulants.
What are the most common side effects people mention with Desoxyn?
Patients often report increased heart rate, insomnia, and appetite suppression. When taken as prescribed, the drug can also cause mood swings or anxiety. The risk of dependence and cardiovascular issues contributes to its cautious use.
Can Desoxyn still be prescribed for ADHD today?
Yes, clinicians may still prescribe Desoxyn for ADHD, but only after evaluating other treatment options and weighing the drug’s higher abuse potential. It remains on the list of prescription stimulants with a high potential for addiction, so its use is closely monitored.
Are there newer alternatives that might replace Desoxyn?
Several newer ADHD medications, such as atomoxetine and lisdexamfetamine, offer effective symptom control with lower abuse risk. Patients and prescribers often consider these options before resorting to Desoxyn.
What does the future look like for Desoxyn’s patent and market position?
With its patents expired and the drug in the public domain, Desoxyn’s market presence is stable but niche. Generic manufacturers can produce the formulation, and any new therapeutic developments would likely focus on safety and delivery improvements rather than patent extensions.
Sources
[1] https://www.drugpatentwatch.com/drug-desoxyn